Ublituximab

Drug Overview

Ublituximab is a high-tech medical treatment that belongs to a class of drugs known as monoclonal antibodies. In the medical world, it is often called a “Smart Drug” or Targeted Therapy. Unlike traditional medicines that might affect the whole body, ublituximab is designed like a guided missile to find and attach to a very specific target on certain cells in the immune system.

For patients and doctors, ublituximab represents a major step forward in treating autoimmune diseases and certain types of blood cancers. By focusing on specific B-cells—the cells that often go wrong in these conditions—the drug can help calm an overactive immune system or destroy cancer cells while trying to spare as much healthy tissue as possible. It is a powerful tool in modern Immunotherapy, used to improve the quality of life for people facing chronic and serious health challenges.

• Generic Name: Ublituximab-xiiy.
• US Brand Names: Briumvi.
• Drug Class: CD20-directed cytolytic monoclonal antibody.
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: FDA-approved for the treatment of relapsing forms of multiple sclerosis (MS) in adults. It is also used in clinical trials for certain leukemias and lymphomas.

What Is It and How Does It Work? (Mechanism of Action)

To understand how ublituximab works, we first need to look at the immune system. The body has “soldiers” called B-lymphocytes (B-cells). In a healthy person, these cells fight off germs. However, in some diseases, these B-cells start attacking the body’s own nerves (as in Multiple Sclerosis) or they start growing out of control (as in Leukemia).

Targeting the CD20 Receptor

Ublituximab is engineered to find a specific protein on the surface of these B-cells called CD20. Think of CD20 as a “lock” and ublituximab as a “key” that only fits that specific lock. When ublituximab finds a B-cell, it latches onto the CD20 receptor. Once it is attached, it triggers three main ways to destroy the cell:

1. Antibody-Dependent Cellular Cytotoxicity (ADCC): This is the drug’s most powerful move. Ublituximab is “glycoengineered,” which means its sugar molecules have been changed to make it stick better to the body’s “natural killer” cells. These killer cells see the tagged B-cell and destroy it immediately.
2. Complement-Dependent Cytotoxicity (CDC): The drug calls in a team of proteins in the blood called the “complement system.” These proteins arrive at the tagged cell and poke holes in its membrane, causing it to pop.
3. Direct Apoptosis: Sometimes, just by latching onto the CD20 lock, ublituximab sends a “suicide signal” into the B-cell, telling it to stop working and die on its own.

By removing these specific B-cells from the blood, ublituximab stops the immune system from attacking the brain and spinal cord in MS patients, or it reduces the number of cancer cells in leukemia patients.

FDA Approved Clinical Indications

Ublituximab has been carefully studied and approved for specific conditions where the immune system needs to be regulated.

Oncological Uses (Investigational)

• Chronic Lymphocytic Leukemia (CLL): Used in combination with other “Smart Drugs” for patients who have not responded to other treatments.
• Non-Hodgkin Lymphoma (NHL): Studied as a targeted therapy for specific types of B-cell lymphomas.

Non-oncological Uses

• Relapsing Forms of Multiple Sclerosis (RMS): This includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

Dosage and Administration Protocols

Ublituximab is given by a healthcare professional as a slow drip into a vein (IV infusion). The schedule is designed to let the body get used to the medicine slowly.

Dose Adjustments

• Renal/Hepatic Insufficiency: Currently, there are no specific dose adjustments required for patients with mild to moderate kidney or liver problems. However, doctors will monitor these patients closely.
• Infusion Reactions: If a patient has a reaction during the drip, the nurse may slow down or pause the infusion.

Clinical Efficacy and Research Results

Clinical trials conducted between 2020 and 2025 have shown that ublituximab is highly effective at stopping disease activity.

Multiple Sclerosis (ULTIMATE I & II Trials)

In two large studies comparing ublituximab to older daily oral medications:

• Relapse Rates: Ublituximab reduced the number of relapses (attacks) by about 50% to 60% compared to the daily pill.
• Brain Lesions: Using MRI scans, researchers found that ublituximab reduced the number of new active brain lesions by over 90%.
• Disability: Many patients saw their disability levels stay the same or even improve over 96 weeks.

Leukemia Research Data

In cancer trials, when ublituximab was combined with other targeted therapies (like umbralisib), the “Overall Response Rate” in patients with CLL was measured at approximately 80%. This means 8 out of 10 patients saw their cancer shrink or disappear for a period of time.

Safety Profile and Side Effects

While ublituximab is a targeted “Smart Drug,” it does affect the immune system, which can lead to side effects.

Black Box Warning

• Hepatitis B Virus (HBV) Reactivation: Before starting, patients must be tested for Hepatitis B. If you have had it before, the drug can “wake up” the virus, causing severe liver damage or death.
• Progressive Multifocal Leukoencephalopathy (PML): Though very rare, other drugs in this class have been linked to a serious brain infection called PML.

Common Side Effects (>10%)

• Infusion Reactions: Fever, chills, headache, flu-like symptoms, or an itchy rash during or shortly after the infusion.
• Respiratory Infections: Frequent colds, sore throats, or sinus infections.
• Lowered Immunoglobulins: A drop in the proteins that help fight infection.

Serious Adverse Events

• Severe Infections: Increased risk of pneumonia or other serious illnesses because the “soldier” B-cells are lowered.
• Fetal Toxicity: The drug can harm an unborn baby. Pregnancy should be avoided.

Management Strategies

• Pre-medication: To prevent reactions, patients are given a steroid, an antihistamine, and a pain reliever (like acetaminophen) 30 to 60 minutes before the infusion.
• Monitoring: Nurses check heart rate and blood pressure every 15 to 30 minutes during the infusion.

Research Areas

Ublituximab is at the center of new research in Immunotherapy and Regenerative Medicine. Scientists are currently looking at how this drug can be used alongside Stem Cell Therapies for MS. The idea is to use ublituximab to “clear out” the bad B-cells and then use stem cells to help repair the damaged protective coating (myelin) on the nerves.

Other research is exploring “combination therapy” in cancer. Doctors are testing if ublituximab can make “Checkpoint Inhibitors” (another type of immunotherapy) work better by preparing the tumor environment for an even stronger attack by the body’s T-cells.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

• Hepatitis B Screening: Mandatory blood test to check for active or past infection.
• Immunoglobulin Levels: To check your baseline ability to fight infections.
• Pregnancy Test: For people of childbearing age.

Precautions During Treatment

• Vaccinations: You should not receive “live” vaccines (like the yellow fever vaccine) while on this drug. All vaccines should be completed at least 4 weeks before starting treatment.
• Pregnancy: Use effective birth control during treatment and for at least 6 months after your last dose.

“Do’s and Don’ts” List

• DO tell your doctor if you have a fever or a cough that won’t go away.
• DO drink plenty of water on the day of your infusion.
• DON’T ignore signs of an infusion reaction, even if they seem mild.
• DON’T skip your 6-month maintenance doses, as the B-cells will return and the disease may become active again.

Legal Disclaimer

The information provided in this guide is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Ublituximab (Briumvi) is a prescription medication and should only be used under the supervision of a qualified healthcare professional. Individual results and survival/relapse rates can vary based on a person’s unique health history. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this document.